[CEMP] Cempra, Inc.

Overview

Type of security: Stock

Sector: Health Care

Industry: Major Pharmaceuticals

Market Capitalization: 887.84 M

Exchange: NASDAQ

The data is delayed by 15 minutes.

 

Price: 6.2 Change: 0.3 (5.08%)
Ext. hours: 6 Change: -0.2 (-3.23%)

chart CEMP

Refresh chart

Description: Cempra, Inc., a clinical-stage pharmaceutical company, focuses on developing antibiotics to meet critical medical needs in the treatment of bacterial infectious diseases in North America. Its two lead product candidates include Solithromycin (CEM-101), which is in a Phase III clinical trial for community-acquired bacterial pneumonia (CABP); and TAKSTA (CEM-102) that is in a Phase II clinical trial for prosthetic joint infections. The company also focuses on using its series of proprietary lead compounds from its novel macrolide library for uses, such as the treatment of chronic inflammatory diseases, endocrine diseases, and gastric motility disorders. It has collaborative research and development and license agreement with Optimer Pharmaceuticals, Inc. The company was formerly known as Cempra Holdings, LLC and changed its name to Cempra, Inc. in February 2012. Cempra, Inc. was founded in 2005 and is headquartered in Chapel Hill, North Carolina.

See how to gain 20% in 14 sec with TrendsInvesting

Fundamental Ratios
Shares Outstanding48.2 M EPS-2.1 EPS Growth - 4 Quarters EPS Growth - Q/Q
EPS Growth - Y/Y Sales Growth - 4 Quarters 636.06% Sales Growth - Q/Q465.3% P/E-1.86
P/E To EPS Growth P/S34.02 P/BV4.81 Price/Cash Per Share
Price/Free Cash Flow-18.07 ROA-27.41% ROE-33.64% ROI
Current Ratio13.32 Quick Ratio Long Term Debt/Equity0.07 Debt Ratio0.09
Gross Margin Operating Margin-228.82% Net Profit Margin-237.76% Dividend Payout Ratio
Dividend Yield
Fundamental Data
Cash From Financing Activities140.64 M Cash From Investing Activities-50 K Cash From Operating Activities-37.3 M Gross Profit
Net Profit-24.97 M Operating Profit-24.35 M Total Assets208.07 M Total Current Assets207.89 M
Total Current Liabilities21.8 M Total Debt18.4 M Total Liabilities45.49 M Total Revenue5.05 M
Technical Data
High 52 week23.56 Low 52 week2.13 Last close2.33 Last change-0.21%
RSI20.41 Average true range0.35 Beta1.77 Volume2.55 M
Simple moving average 20 days-12.52% Simple moving average 50 days-20.99% Simple moving average 200 days-34.78%
Performance Data
Performance Week4.26% Performance Month-26.89% Performance Quart-38.82% Performance Half-38.82%
Performance Year-69.21% Performance Year-to-date-16.96% Volatility daily3.28% Volatility weekly7.34%
Volatility monthly15.03% Volatility yearly52.07% Relative Volume314.45% Average Volume867.08 K
New High New Low

News

2019-03-15 08:02:45 | Edited Transcript of CEMP earnings conference call or presentation 13-Mar-19 8:30pm GMT

2018-11-07 17:31:08 | Edited Transcript of CEMP earnings conference call or presentation 7-Nov-18 1:30pm GMT

2018-05-14 15:41:39 | Edited Transcript of CEMP earnings conference call or presentation 8-May-18 8:30pm GMT

2018-03-13 15:21:12 | Edited Transcript of CEMP earnings conference call or presentation 13-Mar-18 12:30pm GMT

2017-11-22 08:51:01 | Why Earnings Season Could Be Great for Cempra MLNT

2017-11-07 08:20:16 | As merger closes, Cempra now trading as Melinta

2017-11-07 08:13:53 | Cempra, Inc. :CEMP-US: Earnings Analysis: Q3, 2017 By the Numbers : November 7, 2017

2017-11-03 15:30:15 | How Cempra’s shareholder vote on Melinta merger shook out

2017-11-03 11:59:00 | Cempra Announces Preliminary Results of 2017 Stockholder Vote 

2017-11-01 19:51:27 | Is It The Right Time To Buy Cempra Inc CEMP?

2017-11-01 08:25:11 | New CEO in place for Cempra, Melinta combination

2017-11-01 07:00:00 | Melinta and Cempra Announce Accomplished Executive Leadership Team for Combined Organization

2017-10-31 07:00:00 | Melinta and Cempra Name Industry Leader Daniel Wechsler as President and Chief Executive Officer of the Combined Company

2017-10-30 18:21:31 | What You Must Know About Cempra Inc’s CEMP Financial Strength

2017-10-30 11:33:48 | ETFs with exposure to Cempra, Inc. : October 30, 2017

2017-10-26 07:47:00 | 3 Companies Tackling the Antibiotic-Resistant Bacteria Crisis

2017-10-24 08:00:00 | Melinta Therapeutics Publication Reinforces Baxdela Tolerability and Activity in Patients with MRSA Infections and Challenging Comorbidities

2017-10-10 08:00:00 | Melinta Therapeutics’ Topical Radezolid Well Tolerated in Phase 1 Study for Treatment of Acne

2017-10-09 11:22:55 | ETFs with exposure to Cempra, Inc. : October 9, 2017

2017-10-04 13:14:15 | Melinta Therapeutics Presents Outcomes of Baxdela Treatment of Gram-Positive and Gram-Negative Pathogens at IDWeek

2017-09-28 16:15:00 | Cempra and Melinta Announce Expiration of Hart-Scott-Rodino Waiting Period for Proposed Merger

2017-09-28 10:11:04 | ETFs with exposure to Cempra, Inc. : September 28, 2017

2017-09-26 08:00:00 | Melinta Therapeutics Provides for Distribution of Delafloxacin to 19 Countries via Extended Agreement with Eurofarma Laboratórios

2017-09-25 08:00:00 | Melinta Therapeutics Presenting Detailed Analyses from Baxdela Phase 3 ABSSSI Trials and In Vitro Performance against Isolates of Resistant CABP and other Infections

2017-09-10 08:45:00 | SHAREHOLDER ALERT: Monteverde & Associates PC Announces An Investigation Of Cempra, Inc. -- CEMP

2017-09-07 16:15:00 | Cempra Announces Presentations at Upcoming Investor Conferences and Provides Merger Process Update

2017-08-31 17:41:50 | ETFs with exposure to Cempra, Inc. : August 31, 2017

2017-08-25 11:57:50 | Cempra, Inc. :CEMP-US: Earnings Analysis: Q2, 2017 By the Numbers : August 25, 2017

2017-08-11 13:56:28 | [$$] Melinta to Secure Public Listing With Cempra Merger

2017-08-09 22:22:59 | Cempra reports 2Q loss

2017-08-09 16:35:33 | Edited Transcript of CEMP earnings conference call or presentation 9-Aug-17 12:45pm GMT

2017-08-09 11:59:00 | These Two Biotech Stocks Are Going Berserk on Wednesday

2017-08-09 11:02:57 | Cempra joins with Melinta to form new company that intends to go public

2017-08-09 08:45:00 | Malin Investee Company - Melinta Therapeutics - To Be Transformed into a NASDAQ Listed Company

2017-08-09 08:00:00 | Cempra Provides Corporate Update and Reports Second Quarter 2017 Financial Results

2017-08-09 08:00:00 | Cempra and Melinta Announce Merger to Form Leading, Vertically Integrated Commercial-Stage Anti-Infectives Company

2017-08-09 07:00:00 | Investor Network: Cempra, Inc. to Host Earnings Call

2017-07-20 16:05:00 | Cempra to Report Second Quarter 2017 Financial Results

2017-06-30 14:46:54 | ETFs with exposure to Cempra, Inc. : June 30, 2017

2017-06-29 12:20:13 | In case of sale, Cempra execs primed for golden parachutes

2017-06-19 15:04:53 | ETFs with exposure to Cempra, Inc. : June 19, 2017

2017-06-02 13:58:27 | ETFs with exposure to Cempra, Inc. : June 2, 2017

2017-06-02 07:15:00 | Eight Presentations at ASM Microbe Include Late Breaker From Cempra’s Phase 3 Fusidic Acid Study and Solithromycin Data on Gonorrhea and Otitis Media

2017-06-02 07:00:00 | Cempra to Present at the Jefferies 2017 Global Healthcare Conference

2017-05-16 16:55:34 | [$$] Health-Care Investor Agent Capital Seeks $100 Million Fund

2017-05-15 15:26:13 | ETFs with exposure to Cempra, Inc. : May 15, 2017

2017-05-10 07:00:00 | Cempra Presents Data on Ophthalmic Solithromycin at ARVO

2017-05-04 15:47:17 | ETFs with exposure to Cempra, Inc. : May 4, 2017

2017-05-03 10:25:03 | Cempra, Inc. :CEMP-US: Earnings Analysis: Q1, 2017 By the Numbers : May 3, 2017

2017-05-01 17:55:10 | Cempra loses executive, but eyes FDA feedback